Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spontaneous Coronary Artery Dissection in Young Patients: A Case Series and Review of Current Management Algorithm.

Cureus·2023
Same author

Left circumflex STEMI presenting as de Winter sign, an ECG Zebra that gives you the chills! A case report.

Journal of electrocardiology·2023
Same author

Anomalous Origin of the Left Coronary Artery From the Right Coronary Cusp: A Case Report.

Cureus·2023
Same author

Rupture of Both Left-Sided Valves Following Endocarditis Causing One Trouble After Another: A Case Report.

Cureus·2022
Same author

Outlet Ventricular Septal Defect in an Elderly Male.

Cureus·2021
Same author

Inhibition of HINT1 Modulates Spinal Nociception and NMDA Evoked Behavior in Mice.

ACS chemical neuroscience·2019

Related Experiment Video

Updated: Jun 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Fixing the "broken heart": pharmacologic implications.

Rachit M Shah1, Vamsi K Kodumuri, Rohit Bhuriya

  • 1Department of Cardiology, Rosalind Franklin University/Chicago Medical School, IL, USA.

American Journal of Therapeutics
|December 15, 2010
PubMed
Summary
This summary is machine-generated.

Broken-heart syndrome, or stress-induced cardiomyopathy, mimics heart attacks. This review explores its mechanisms and the role of medications like aspirin and beta blockers in treatment and prevention.

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

Related Experiment Videos

Last Updated: Jun 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

Area of Science:

  • Cardiology
  • Cardiovascular Medicine

Background:

  • Broken-heart syndrome, also known as Takotsubo cardiomyopathy, presents similarly to acute coronary syndrome.
  • It accounts for 1%-2% of ST-elevation myocardial infarction cases.
  • Intense emotional or physiological stress is a presumed trigger.

Purpose of the Study:

  • To review the pathophysiologic mechanisms of Takotsubo cardiomyopathy.
  • To discuss the pharmacological implications and treatment strategies for this condition.

Main Methods:

  • Literature review of studies on Takotsubo cardiomyopathy.
  • Analysis of proposed pathophysiologic mechanisms.
  • Evaluation of the role of various medications in management.

Main Results:

  • Takotsubo cardiomyopathy shares clinical and electrocardiographic features with acute myocardial infarction.
  • Pathophysiology remains incompletely understood, with stress as a key factor.
  • Empirical and supportive management is current practice.

Conclusions:

  • Understanding the pathophysiology of Takotsubo cardiomyopathy is crucial for targeted treatment.
  • Medications such as aspirin, beta blockers, ACE inhibitors, and statins may play a role in treatment and prevention.
  • Further research is needed to clarify management guidelines.